Meeting
2022 ASCO Annual Meeting
Assessment of FOXC1 expression as a predictor of response to neoadjuvant taxane plus platinum regimens in primary triple-negative breast cancer: Retrospective analysis of three clinical trial cohorts.
Authors
Partha Ray
Onconostic Technologies, Evanston, IL
Partha Ray , Tania Ray , Sara Lopez-Tarruella Cobo , Maria del Monte Millan , Enrique Álvarez , Yolanda Jerez Gilarranz , Marta Roche , Clive R. Taylor , Miguel Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 569)
DOI
10.1200/JCO.2022.40.16_suppl.569
Abstract #
569
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
First Author: Cheng Wang
Poster
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Laura Spring
Poster
2021 ASCO Annual Meeting
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
First Author: Fangchao Zheng
Poster
2019 ASCO Annual Meeting
Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).
First Author: Priyanka Sharma